signed an agreement with Elusys
Therapeutics for the manufacture of Anthin™, Elusys’ late -stage mAb against inhaled anthrax
. Under terms of the deal, Lonza will provide process development services and manufacture the product using its GS Gene Expression System
Anthin is a humanized, deimmunized mAb that targets the protective antigen of B. anthracis and neutralizes the effects of anthrax toxins. The antibody is being developed for both the prevention and treatment of inhalation anthrax. Elusys has been awarded $34 million from the NIH and DOD for development of the antibody. The product has also been granted fast-track status and orphan drug designation by the FDA.